Västra Hamnen: Heliospectra - Pandemic taking its toll
Västra Hamnen Corporate Finance has released a research update on Heliospectra AB following the company's report for Q2 2020. The pandemic has caused among the lowest sales and order figures for years and another capital injection might be unavoidable. We lower our valuation interval to SEK 5.00 - 7.50 per share, writes Västra Hamnen.· Both sales and order intake are hit hard by the pandemic · We anticipate another capital injection in Q1 or sooner · We lower our valuation interval to SEK 5.00 – 7.50 per share Last Friday, Heliospectra presented its Q2 report and it stands clear